Adaptimmune Therapeutics (ADAP)
0.52
-0.02 (-3.70%)
At close: Mar 03, 2025, 3:59 PM
0.51
-2.46%
After-hours: Mar 03, 2025, 04:00 PM EST
Adaptimmune Therapeutics Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Revenue | 60.28M | 27.15M | 6.15M | 3.96M | 1.12M | 59.51M | 37.83M | 14.2M | 10.72M | 604.63K | n/a |
| Cost of Revenue | 9.86M | 127.73M | 111.09M | 91.57M | 97.5M | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross Profit | 50.42M | -100.58M | -104.94M | -87.61M | -96.38M | 59.51M | 37.83M | 14.2M | 10.72M | 604.63K | n/a |
| Operating Income | -138.04M | -163.97M | -162.25M | -133.41M | -139.77M | -82.36M | -80.66M | -72.8M | -23.07M | -14.37M | -9.35M |
| Interest Income | 5.96M | 1.54M | 1.09M | 2.31M | 2.77M | 2.85M | 2.23M | 1.11M | 787K | 3.41K | 13.68K |
| Pretax Income | -112.53M | -162.96M | -157.3M | -129.93M | -136.92M | -95.02M | -69.69M | -70.69M | -23.69M | -14.37M | -9.34M |
| Net Income | -113.87M | -165.46M | -158.09M | -130.09M | -137.16M | -95.51M | -70.14M | -71.58M | -21.59M | -12.7M | -8.46M |
| Selling & General & Admin | 71.81M | 63.39M | 57.3M | 45.8M | 43.39M | 43.6M | 31.11M | 23.21M | 11.32M | 2.73M | 1.21M |
| Research & Development | 126.51M | 127.73M | 111.09M | 91.57M | 97.5M | 98.27M | 87.39M | 63.79M | 23.19M | 12.53M | 8.15M |
| Other Expenses | n/a | -536K | 3.85M | 1.16M | 75K | -15.5M | 8.74M | 1M | -726.5K | -281.02K | n/a |
| Operating Expenses | 188.42M | 191.11M | 168.4M | 137.36M | 140.89M | 141.87M | 118.49M | 87M | 33.79M | 14.98M | 9.35M |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | 376K | 2.23M | n/a | n/a | 6.81K | 6.08K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 198.28M | 191.11M | 168.4M | 137.36M | 140.89M | 141.87M | 118.49M | 87M | 33.79M | 14.98M | 9.35M |
| Income Tax | 1.34M | 2.5M | 791K | 162K | 242K | 497K | 451K | 892K | -2.11M | -1.67M | -878.67K |
| Shares Outstanding (Basic) | 1.21B | 967.24M | 934.83M | 854.78M | 629.81M | 584.34M | 527.64M | 424.71M | 214.7M | 304.33M | 101.18M |
| Shares Outstanding (Diluted) | 1.21B | 967.24M | 934.83M | 854.78M | 629.81M | 584.34M | 527.64M | 424.71M | 214.7M | 304.33M | 101.18M |
| EPS (Basic) | -0.09 | -0.17 | -0.17 | -0.15 | -0.22 | -0.16 | -0.13 | -0.17 | -0.1 | -0.04 | -0.08 |
| EPS (Diluted) | -0.09 | -0.17 | -0.17 | -0.15 | -0.22 | -0.16 | -0.13 | -0.17 | -0.1 | -0.04 | -0.08 |
| EBITDA | -128.2M | -155.59M | -155.68M | -125.81M | -131.76M | -74.56M | -75.24M | -69.51M | -23.77M | -23.91M | -11.28M |
| Depreciation & Amortization | 9.84M | 6.07M | 6.57M | 7.65M | 8.04M | 7.81M | 5.42M | 3.29M | 732.78K | 250.37K | 45.6K |